Publication:
Inflammation, a common mechanism in frailty and COVID-19, and stem cells as a therapeutic approach

dc.contributor.authorBecerra, José
dc.contributor.authorDuran, Ivan
dc.contributor.authoraffiliation[Becerra,J; Duran,I] Department of Cell Biology, Genetics, and Physiology, Faculty of Sciences, University of Málaga, IBIMA, Málaga, Spain. [Becerra,J; Duran,I] Networking Biomedical Research Center in Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), Andalusian Centre for Nanomedicine and Biotechnology-BIONAND, Málaga, Spain.
dc.date.accessioned2024-02-19T15:30:26Z
dc.date.available2024-02-19T15:30:26Z
dc.date.issued2021-08-03
dc.description.abstractAs our life expectancy increases, specific medical conditions appear, and new challenges are met in terms of global health. Frailty has become a medical and scientific concept to define pathologies where inflammation, depressed immune system, cellular senescence, and molecular aging converge. But more importantly, frailty is the ultimate cause of death that limits our life span and deteriorates health in an increasing proportion of the world population. The difficulty of tackling this problem is the combination of factors that influence frailty appearance, such as stem cells exhaustion, inflammation, loss of regeneration capability, and impaired immunomodulation. To date, multiple research fields have found mechanisms participating in this health condition, but to make progress, science will need to investigate frailty with an interdisciplinary approach. This article summarizes the current efforts to understand frailty from their processes mediated by inflammation, aging, and stem cells to provide a new perspective that unifies the efforts in producing advanced therapies against medical conditions in the context of frailty. We believe this approach against frailty is particularly relevant to COVID-19, since people in a state of frailty die more frequently due to the hyperinflammatory process associated with this infection.
dc.description.sponsorshipUniversity of Malaga (Plan Propio); Regional Government of Andalusia; Iniciativa Ingenio 2010, Consolider Program, CIBER Actions, the Instituto de Salud Carlos III; Spanish Network on Cell Therapy, Grant/Award Number: RD16/0011/0022; Junta de Andalucia, Grant/Award Numbers: UMA18-FEDERJA-177, CV20-81404.
dc.identifier.doi10.1002/sctm.21-0074
dc.identifier.e-issn2157-6580es_ES
dc.identifier.issn2157-6564
dc.identifier.journalStem Cells Translational Medicinees_ES
dc.identifier.otherhttp://hdl.handle.net/10668/3457
dc.identifier.pubmedID34164948es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18425
dc.language.isoeng
dc.publisherAlphaMed Press, Inc.
dc.relation.publisherversionhttps://academic.oup.com/stcltm/article/10/11/1482/6517841?login=falsees
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAging
dc.subjectCOVID-19
dc.subjectFrailty
dc.subjectImmunomodulation
dc.subjectInflammation
dc.subjectMesenchymal stem cell
dc.subjectMSC
dc.subjectRegeneration
dc.subjectStem cell exhaustion
dc.subjectEnvejecimiento
dc.subjectFragilidad
dc.subjectInmunomodulación
dc.subjectInflamación
dc.subjectCélulas madre mesenquimatosas
dc.subjectRegeneración
dc.subject.meshAging
dc.subject.meshHumans
dc.subject.meshImmunomodulation
dc.subject.meshInflammation
dc.subject.meshCoronavirus Infections
dc.subject.meshPlasma Skin Regeneration
dc.subject.meshLight Signal Transduction
dc.subject.meshCoronavirus Infections
dc.subject.meshMesenchymal Stem Cell Transplantation
dc.titleInflammation, a common mechanism in frailty and COVID-19, and stem cells as a therapeutic approach
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files